AstraZeneca’s Alexion wants to make sure rare is still seen and heardnews2022-03-03T11:07:44+00:00March 3rd, 2022|Fierce Pharma|
AstraZeneca’s Alexion to amplify the voices of rare disease, with a focus on diversity in diagnosisnews2022-03-03T11:07:44+00:00March 3rd, 2022|Fierce Pharma|
Argenx straddles the line between drug promotion and awareness in latest unbranded DTC TV adnews2022-03-03T10:13:13+00:00March 3rd, 2022|Fierce Pharma|
Merck loses another vet, this time bidding adieu to chief patient officer Gerberdingnews2022-03-02T20:27:04+00:00March 2nd, 2022|Fierce Pharma|
As Eli Lilly grows beyond Research Triangle Park, biopharmas big and small are tapping North Carolina’s ‘limitless’ potentialnews2022-03-02T15:43:38+00:00March 2nd, 2022|Fierce Pharma|
Novartis sells pair of manufacturing plants as Sandoz strategic review rolls onnews2022-03-02T15:25:57+00:00March 2nd, 2022|Fierce Pharma|
FDA says no, thank you to Xpovio’s cancer expansion bid, prompting Karyopharm to run new studynews2022-03-02T15:09:02+00:00March 2nd, 2022|Fierce Pharma|
Heron’s opioid alternative Zynrelef, slated for blockbuster status, hits a rough Q4 as Jefferies seek ‘launch clarity’news2022-03-02T15:02:57+00:00March 2nd, 2022|Fierce Pharma|
A year later at the SOTU, deja vu all over again as Biden calls for lower drug prices, zeroing in on insulinnews2022-03-02T14:26:19+00:00March 2nd, 2022|Fierce Pharma|
Pfizer, following last year’s Chantix recall, pulls blood pressure med in Canada on carcinogen fearsnews2022-03-02T14:16:26+00:00March 2nd, 2022|Fierce Pharma|
